首页工具

购物车

Laquinimod

产品编号 T6561 CAS 248281-84-7

别名: LAQ, ABR-215062, 拉喹莫德

Laquinimod (LAQ) 是一种免疫调节剂，可预防中枢神经系统的神经变性和炎症。

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Laquinimod, CAS 248281-84-7

规格	价格/CNY	货期
1 mg	￥ 329	现货
2 mg	￥ 472	现货
5 mg	￥ 815	现货
10 mg	￥ 1,320	现货
25 mg	￥ 2,190	现货
50 mg	￥ 3,230	现货
100 mg	￥ 4,780	现货
500 mg	￥ 9,870	现货
1 mL * 10 mM (in DMSO)	￥ 643	现货

大包装超大折扣，点击咨询

其他形式的 Laquinimod:

Laquinimod sodium
询价

选择批次

纯度: 98.84%

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

相关产品

产品描述	Laquinimod (LAQ) is an effective immunomodulator, which is currently under development in phase III trials for the treatment of multiple sclerosis as an oral therapy.
体外活性	Laquinimod treatment at 0.1-1 μM does not affect the viability of peripheral blood mononuclear cells (PBMC). By performing the large-scale gene expression microarray analysis in PBMC from healthy subjects or relapsing-remitting multiple sclerosis (RRMS) patients, Laquinimod is shown to induce suppression of genes related to antigen presentation and corresponding inflammatory pathways. Laquinimod induces activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells. Laquinimod displays significant effects on immune modulation related to the suppression of antigen presenting mechanism followed by a decrease of chemotaxis and adhesion, and exhibits potent anti-inflammatory potency through the suppression of the NF-κB pathway that concordantly leads to the activation of apoptosis of immuno-competent cells. [5]
体内活性	Administration of Laquinimod (0.16-16 mg/kg/day) dose-dependently inhibits the incidence of experimental autoimmune neuritis (EAN) in Lewis rats, ameliorates Clinicalal signs and inhibits P0 peptide 180-199-specific T cell responses as well as the inflammation and demyelination in the peripheral nerves, suggesting that Laquinimod may mediate its effects by regulation of Th1/Th2 cytokine balance. [1] Laquinimod significantly inhibits the development of murine acute experimental autoimmune encephalomyelitis (EAE), being approximately 20 times more potent than the immunomodulator roquinimex. [2] Laquinimod treatment inhibits the development of experimental autoimmune encephalomyelitis (EAE) in the Lewis rat in a dose-dependent manner, and shows better disease inhibitory effects as compared to roquinimex (Linomide). [3] Laquinimod potently inhibits the development of chronic experimental autoimmune encephalomyelitis (chEAE) in IFN-beta k.o. mice and wild type mice. [4] Laquinimod reduces Clinicalal signs, inflammation, and demyelination in C57BL/6 mice with active EAE induced with MOG(35-55) peptide, and down-regulates VLA-4-mediated adhesiveness and pro-inflammatory cytokines such as IL-17. [6] The study of Laquinimod in the mice model of EAE using a conditional BDNF knockout strain lacking BDNF expression in myeloid cells and T cells (LLF mice) indicates Laquinimod also modulates autoimmune demyelination via induction of brain-derived neurotrophic factor (BDNF). [7]
细胞实验	The peripheral blood mononuclear cells (PBMC) are incubated with Laquinimod for 24 hours. Cell viability is measured on total PBMC by propidium iodide (PI) staining using an automated cell counter. Protein expression level is assessed in PBMC samples by Western blot using anti-HLA-DQA/DQB monoclonal antibodies.(Only for Reference)

别名	LAQ, ABR-215062, 拉喹莫德
分子量	356.8
分子式	C19H17ClN2O3
CAS No.	248281-84-7

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

Ethanol: 1 mg/mL (2.8 mM)

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 57 mg/mL (159.8 mM)

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.8027 mL	14.0135 mL	28.0269 mL	70.0673 mL
DMSO	5 mM	0.5605 mL	2.8027 mL	5.6054 mL	14.0135 mL
	10 mM	0.2803 mL	1.4013 mL	2.8027 mL	7.0067 mL
	20 mM	0.1401 mL	0.7007 mL	1.4013 mL	3.5034 mL
	50 mM	0.0561 mL	0.2803 mL	0.5605 mL	1.4013 mL
	100 mM	0.028 mL	0.1401 mL	0.2803 mL	0.7007 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Zou LP, et al. Neuropharmacology, 2002, 42(5), 731-739. 2. Brunmark C, et al. J Neuroimmunol, 2002, 130(1-2), 163-172. 3. Yang JS, et al. J Neuroimmunol, 2004, 156(1-2), 3-9. 4. Runström A, et al. J Neuroimmunol, 2006, 173(1-2), 69-78. 5. Gurevich M, et al. J Neuroimmunol, 2010, 221(1-2), 87-94.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +

% Tween 80+

% ddH₂O

%DMSO+

计算重置

计算结果如下:

工作液浓度: mg/ml;

母液配置方法: mg 药物溶于 μL DMSO (母液浓度为 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 μL DMSO 主液，加入 μL PEG300，混匀澄清，再加 μL Tween 80，混匀澄清，再加 μL ddH₂O, 混匀澄清。

备注:

要按顺序从左向右依次添加助溶剂。可配合物理方法，如涡流、超声波或热水浴使之帮助溶解。

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到，包括如何准备库存溶液，如何存储产品，以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Laquinimod 248281-84-7 Apoptosis NF-Κb Others NF-κB inhibit multiple sclerosis relapsing remitting carboxamide Nuclear factor-kappaB Inhibitor ABR 215062 Nuclear factor-κB immunomodulator ABR215062 chronic progressive neurodegenerative disease LAQ ABR-215062 inflammation 拉喹莫德 Orally neurodegeneration inhibitor

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

沪公网安备 31010602006700号

陶术

生物

TargetMol^®中国区唯一合作伙伴

点击进入陶术生物官网

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼

Laquinimod

存储

溶解度

溶液配制表

计算器

输入分子式，点击计算，可计算出产品的分子量。

参考文献

相关产品

相关化合物库

剂量换算

体内实验配液计算器

技术支持

Keywords